Impact of obesity on chemotherapy-induced muscle mitochondrial dysfunction
Description: PROJECT NARRATIVE Obesity increases the risk of cancer; thus, individuals that are obese are more likely to undergo chemotherapy in their lifetime. While it is common practice to apply a dosing cap, current recommendations for the treatment of obese cancer patients is full body surface area chemotherapy dosing regimens despite some evidence suggesting that these patients may have exacerbated drug toxicities including perturbations to skeletal muscle mitochondrial function. The primary goal of my proposed F31 is to 1) understand the impact of obesity on chemotherapy-induced skeletal muscle mitochondrial dysfunction and 2) provide mechanistic and therapeutic insights aimed at better improving chemotherapy tolerance with obesity.
Funder: National Cancer Institute
Funding type: fellowship
Funder scheme: F31
Start date: 2023-07-01
End date: 2026-06-30
Investigator: THOMAS CARDACI
Institution: UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
Funded outputs count: 10
Funder award ID: F31CA278490
OpenAlex ID: G6868356607